We are a clinical stage biotechnology company focused on the development of novel therapeutics and diagnostics in oncology, neurology, and rare pediatric diseases, medical countermeasures, and viral disease.

Our vision is to deliver promising, transformative science to underserved patients. Our name symbolizes our mission to partner with clinicians and scientists to help people who are in urgent need.

Pipeline

Pipeline

Pipeline

Advancing novel therapeutics and radioimaging agents with standards of excellence in several degenerative disease areas.

Technology

Our world class research

drives life-changing innovation for patients in oncology, neurology, and

rare pediatric diseases.

Partnerships

Collaborate with us to leverage our technologies and expertise to discover, develop, and deliver ground-breaking results to patients.

Family Visit

untitled image

Making a Difference in People's Lives

Diverse group of mothers and daughters.jpg

Medical equipment.jpg Doctor and patient in the room of computed tomography at hospital.jpg

The vast majority of rare pediatric diseases have no method of effective diagnosis. AIP is passionate about developing PET imaging agents for these maladies because we know this will lead to faster and better innovation in developing cures.

4.8 years

average wait from first symptom to diagnosis

for rare pediatric disease[1]

Our innovations in drug development help families to find a clearer pathway to diagnosis of children's rare diseases. That's impactful; and it's what drives us every day at AIP.

Roseanne Satz, Chief Executive Officer and Founder

Our team has deep knowledge in radiation physics, leading to advances in the use of Positron Emission Tomography and Peptide Receptor Radionuclide Therapy.

If you have a question and would like

to contact us, please reach out.